Updated:
Illumina Ventures
Illumina Ventures is the independent genomics venture firm co-founded by Nick Naclerio.
Illumina Ventures
Illumina Ventures was established as an independently managed venture firm, built on a strategic relationship with Illumina (NASDAQ: ILMN) — the dominant player in DNA sequencing. Founding Partner Nick Naclerio, Ph.D., drives the firm's investment strategy alongside a deep bench of Ph.D.-level partners across US and European offices. Its capital flows into early-stage companies across four verticals: life sciences tools, diagnostics, therapeutics, and digital health. Confirmed portfolio positions include Arbor Biotechnologies in gene editing, Delfi Diagnostics in early cancer detection, and Iambic Therapeutics in AI-discovered medicines. The firm also runs Illumina Ventures Labs, an accelerator that provides sequencing access, mentorship, and lab space to pre-seed genomics startups, adding an origination pipeline distinct from standard venture deal flow. In April 2025, the firm welcomed DeepSeq.AI into its Labs program, continuing a pattern of backing startups at the intersection of AI and multi-omics. The portfolio reflects a transatlantic reach — investments span companies headquartered in the US and Europe, including France's Stilla Technologies and Ireland's Sonothera. What sets Illumina Ventures apart is its hybrid architecture: it operates with full independence from its corporate namesake while leveraging Illumina's technology stack and commercial relationships to validate and accelerate portfolio companies — a structure closer to a corporate-venture offshoot with fund-level autonomy rather than a captive strategic arm.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Tarrytown
Corporate office
Tarrytown, NY, United States
Additional offices
San Francisco Bay Area · Europe Office
Principals
Nick Naclerio
Founding Partner
Abhijit Mazumder
Partner
Wouter Meuleman
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Illumina Ventures?
Founding Partner Nick Naclerio, Ph.D., leads the investment team and sets the firm's thesis. He is supported by partners including Abhijit Mazumder, Wouter Meuleman, and others, all of whom hold advanced scientific degrees. The firm operates with an independent investment committee despite its strategic link to Illumina.
Is Illumina Ventures the corporate venture capital arm of Illumina?
No. Illumina Ventures is independently managed and makes its own investment decisions. While it maintains a strategic relationship with Illumina and benefits from access to its technology and expertise, it is not a captive corporate venture unit. The firm raises external capital and operates with a standard venture fund structure.
What is Illumina Ventures Labs?
Illumina Ventures Labs is the firm's accelerator program for very early-stage genomics startups. Participating companies receive access to sequencing infrastructure, fully equipped lab space, mentorship from the firm's partners, and seed capital. The program acts as a pre-investment pipeline, often leading to a first institutional round led by Illumina Ventures.
Which sectors does Illumina Ventures explicitly avoid?
The firm focuses tightly on genomics-enabled health and sustainability. It does not invest outside of its four stated verticals: life sciences tools, diagnostics, therapeutics, and digital health. Pure software plays, traditional healthcare services without a genomics component, and non-science-based consumer health apps fall outside the mandate.
Does Illumina Ventures lead rounds or primarily follow on?
Illumina Ventures leads Seed and Series A rounds in its core genomics verticals. The firm often acts as the first institutional investor, particularly for companies emerging from its Labs program. For later-stage financings within the portfolio, it participates as a follow-on investor, frequently alongside top-tier life sciences VCs.
How does Illumina Ventures source proprietary deal flow?
Deal flow comes through three main channels: the Illumina Ventures Labs accelerator, which seeds pre-institutional companies; the strategic relationship with Illumina, which surfaces startups using the sequencing giant's platforms; and the partners' deep academic and industry networks across the US and Europe. This combination gives the firm early visibility into breakthroughs in single-cell analysis, spatial biology, and AI-driven drug discovery.
What is the geographic scope of Illumina Ventures' investments?
The firm invests primarily in North America and Europe. Its portfolio includes US-based companies like Delfi Diagnostics and Arbor Biotechnologies, as well as European companies such as Stilla Technologies (France) and Sonothera (Ireland). The firm has offices in the San Francisco Bay Area and a dedicated Europe office to serve both markets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: